IDT Biologika
End-to-End Contract Development and Manufacturing of Vaccines and Biologics
About IDT Biologika
Contract Development and Manufacturing of Vaccines and Biologics
IDT Biologika specializes in the contract development and manufacturing of vaccines, gene therapy medicinal products, sterile liquids and lyophilized biologics. We
help biopharmaceutical companies with the challenging and complex process of
translating vaccines and other biopharmaceuticals from the research lab through
clinical development to large-scale commercial manufacturing including fill/finish, packaging
and quality control. IDT Biologika provides fully integrated services for GMP compliant end-to-end services in BSL2 facilites meeting FDA and EMA standards (ANVISA ready).
We strive for strong and enduring partnerships with innovative biotech and world‘s
leading biopharma companies. Our almost 100-year tradition of manufacturing
vaccines and biopharmaceuticals motivates and obligates us to advance our clients’
products to prevent and treat diseases that impact the health of people worldwide.
Friday, 5. July 2019
New building for vaccine production enables even more flexible reaction to customer demands more info
Wednesday, 3. July 2019
Ceva completes acquisition of IDT veterinary business assets, moving closer to its 2020 objective of 50:50 bio-pharma split more info
Wednesday, 5. June 2019
Divestment of animal health business unit enables focus on global growth market more info
Friday, 17. May 2019
Ceva Santé Animale and IDT Biologika GmbH announce agreement for Ceva to acquire the IDT animal health business, expanding its global vaccine portfolio and boosting swine innovation more info
Tuesday, 26. March 2019
IDT Biologika Receives Six 2019 CMO Leadership Awards more info